Maines, L.W.; Keller, S.N.; Smith, R.A.; Green, C.L.; Smith, C.D.
The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy. Int. J. Mol. Sci. 2024, 25, 2322.
https://doi.org/10.3390/ijms25042322
AMA Style
Maines LW, Keller SN, Smith RA, Green CL, Smith CD.
The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy. International Journal of Molecular Sciences. 2024; 25(4):2322.
https://doi.org/10.3390/ijms25042322
Chicago/Turabian Style
Maines, Lynn W., Staci N. Keller, Ryan A. Smith, Cecelia L. Green, and Charles D. Smith.
2024. "The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy" International Journal of Molecular Sciences 25, no. 4: 2322.
https://doi.org/10.3390/ijms25042322
APA Style
Maines, L. W., Keller, S. N., Smith, R. A., Green, C. L., & Smith, C. D.
(2024). The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy. International Journal of Molecular Sciences, 25(4), 2322.
https://doi.org/10.3390/ijms25042322
